Completed PHASE1 INTERVENTIONAL 1-arm NCT04080609

DDI Study Between Dorzagliatin and Rifampicin

A Single Dose, Open Label, Drug-drug Interaction Study to Investigate the Pharmacokinetics and Safety of Dorzagliation Administered Alone or in Combination With Rifampicin in Healthy Subjects

Sponsor: Hua Medicine Limited

Conditions Drug Interaction

Interventions Dorzagliatin

Updated 4 times since 2019 Last updated: Sep 4, 2019 Started: Mar 27, 2018 Primary completion: Apr 17, 2018 Completion: Apr 17, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Drug Interaction and is currently completed. Hua Medicine Limited leads this study, which shows 4 recorded versions since 2018 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Oct 2019 — Jan 2021 [monthly]

Completed PHASE1

First recorded

Mar 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hua Medicine Limited

Data source: Hua Medicine Limited

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China